N/A
Completed N=30
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Source: ClinicalTrials.gov NCT05986682 ↗Enrolled (actual)
30
Serious AEs
—
Results posted
Feb 2025
Primary outcomePrimary: Treatment Characteristics: Duration of Treatment With BLENREP — 9.3 Months
Summary
The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Characteristics: Duration of Treatment With BLENREP |
9.3 | — |
| PRIMARY Treatment Characteristics: Discontinuation of BLENREP Treatment |
26; 22; 4; 3; 3 | — |
| PRIMARY Treatment Characteristics: Dosing Patterns - Number of Cycles of Treatment With BLENREP Therapy |
6.5; 2; 3 | — |
| PRIMARY Treatment Characteristics: Dosing Patterns - Delays in Treatment With BLENREP Therapy |
27; 27; 2; 3; 2; 10 | — |
| PRIMARY Treatment Characteristics: Dosing Patterns - Dose Reductions During Treatment With BLENREP Therapy |
19; 13; 6; 1 | — |
| PRIMARY Clinical Outcomes: Best Overall Response |
0; 11; 9; 9; 1 | — |
| PRIMARY Clinical Outcomes: Time To Response |
1.4 | — |
| PRIMARY Clinical Outcomes: Time To Best Response |
1.5 | — |
| PRIMARY Clinical Outcomes: Duration of Response |
9.8 | — |
| PRIMARY Clinical Outcomes: Progression-Free Survival (PFS) |
8.4 | — |
| PRIMARY Clinical Outcomes: Overall Survival (OS) |
19; 10; 1 | — |
| SECONDARY Ophthalmology: Presence of Ocular Toxicity |
28; 27 | — |
| SECONDARY Ophthalmology: Number of Ocular Toxicity Events Per Participant |
10.5; 7 | — |
| SECONDARY Ophthalmology: Treatments for Ocular Toxicity |
30; 15; 10; 11; 1 | — |
| SECONDARY Magnitude of Distress Using National Comprehensive Cancer Network Distress Thermometer (NCCN DT) |
1.33 | — |
| SECONDARY Sources of Distress Using NCCN DT: Frequency of Reported Problems |
27; 17; 46; 107; 23 | — |
| SECONDARY Sources of Distress Using NCCN DT: Top 5 Most Frequently Reported Problems |
69; 63; 40; 33; 31 | — |
| SECONDARY Healthcare Resource Utilization (HCRU) |
3; 7; 10; 20; 11; 10 | — |
Eligibility Criteria
Inclusion Criteria
- Age > 18 years of age as of start of treatment with BLENREP
- Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
- Patients with a record of starting treatment with BLENREP for RRMM between August 5, 2020 and November 22, 2022.
- Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.
Exclusion Criteria
- Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
- Age > 89 years of age as of start of index therapy
Data sourced from ClinicalTrials.gov (NCT05986682). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.